Yes, when they are two different drugs and one of them is a chemotherapy or highly complex biologic. The 96401 / 96372 edit has modifier indicator 1, so the 96372 line (column 2) carries XU or 59; 96401 stands on its own. Two SC injections of the same substance, or a second non-chemo drug, do not create a 96401.
The 96372 / 96401 pair as it stands in the CMS PTP tables for 2026q3 (as of 2026-07-01), identical on the practitioner and hospital-outpatient tables:
96372 (column 2) denies as included in 96401 (column 1) unless the 96372 line carries a distinct-service modifier — XU or 59 — and the record supports a distinct service.
Column 1 96401 · column 2 96372 · edit effective January 2009.
Same edit, same direction: column 1 96401, column 2 96372, since January 2009. A UB-04 carrying 96401 and 96372 is adjudicated exactly as the CMS-1500 is.
The pair shows up wherever a subcutaneous chemotherapy or targeted biologic is given in the office next to something ordinary: bortezomib plus denosumab in myeloma, a subcutaneous immunotherapy plus a B12 injection, subcutaneous rituximab plus a steroid. The 96401 / 96372 split is about the drug, not the technique — the same needle in the same abdomen earns 96401 when the substance is on the chemo/complex list and 96372 when it is not.
NCCI has paired 96401 (column 1) with 96372 (column 2) at modifier indicator 1 since January 2009. The edit denies the 96372 as included unless the line carries a distinct-service modifier; XU is the specific one and 59 remains valid. The justification is the second, different substance by its own order — it does not require a separate encounter or site, only documentation that two drugs were injected.
Units: 96401 has a practitioner MUE of 3 per date of service, 96372 of 4. Both drugs appear on their own J-code lines with their own units (J9041 in 0.1 mg units, J0897 in 1 mg units in the example), and single-dose vials that were not fully used carry JW for the discarded amount — the bortezomib line in the worked claim shows that split.
It is a distinct service by drug, not by encounter: one substance from the chemotherapy/complex-biologic family and one from outside it, each with its own order and injection site. The modifier goes on 96372 regardless of which was given first.
| Code | Descriptor | Practitioner MUE / day | Facility MUE / day | Adjudication · rationale |
|---|---|---|---|---|
96372 | therapeutic, prophylactic or diagnostic injection, SC or IM | 4 | 5 | MAI 3 · Clinical: Data |
96401 | chemotherapy or highly complex biologic injection, SC or IM | 3 | 4 | MAI 3 · Clinical: Data |
96372 and 96401 are MAI 3: units are summed across the date of service, and a documented medical-necessity appeal can pay units above the limit. Other codes: MUE lookup.
The 96372 / 96401 answer rests on H10 in the claim builder’s rule set (source: CPT 2026 hydration / therapeutic infusion guidelines · CMS Pub 100-04 ch. 12 §30.5), the rule it applies when it places a line by route:
…a subcutaneous or intramuscular therapeutic injection reports 96372 (96401 chemo/biologic)… Full text of H10
Related hierarchy rules for this claim: H5 (CPT 2026 hydration / therapeutic infusion guidelines).
CO-97 on 96372 with 96401. Add XU to the 96372 line and resubmit with the MAR listing both drugs and routes. A denial on 96401 itself usually means the payer disputes the drug’s classification — cite the drug’s CPT/NCCI status as a chemotherapeutic or complex biologic.
The median payer contract pays 126–134% of Medicare on 96372, 96401. On 96372 the highest payer median is Blue Shield of California’s $67.48 and the lowest BCBS Arizona’s $10.96, against Medicare’s $15.36; Blue Shield of California is highest on 2 of the 2 lines. Pick a state below for each payer’s own number where you bill.
| Code | Medicare (PFS, office) | Median payer contract | Middle half of payer medians | Payers |
|---|---|---|---|---|
96372 | $15.36 | $19.31 (126%) | $17.22–$24.16 | 37 |
96401 | $71.81 | $96.46 (134%) | $83.62–$102.54 | 37 |
3,529 payer×state medians for 96372, 96401 from 37 payers’ Transparency-in-Coverage files (2026-Q2-06); Medicare = national non-facility PFS.
This claim priced by your payer — Velcade’s rate on the drug line, 96372 and 96401 at the payer’s contracted amount, the payer’s policy on Velcade (prior auth, covered diagnoses), and the patient’s share — is the same claim in your free account.
Price this claim for your payer — start free →
Free 30-day trial, no card. The claim above opens in Claim Check with the drug, dose, setting and your payer already filled in.
Yes: 96401 for the bortezomib and 96372-XU for the dexamethasone (J1100), two J-code lines. The 96401 / 96372 edit applies exactly as in the denosumab example; the modifier sits on the 96372 line.
No. Each chemotherapy or complex-biologic injection is its own unit of 96401 (practitioner MUE 3 per day); 96372 is only for a substance outside that family. Two units of 96401 carry no PTP edit against each other.
CPT applies 96401–96549 to antineoplastics and to non-antineoplastic biologic-response modifiers and monoclonal antibodies that carry the same monitoring burden — bortezomib, subcutaneous rituximab and daratumumab, for example. Denosumab, B12, steroids and antiemetics are 96372. When a payer publishes its own list, its list governs its claims.